Combination of dexmedetomidine and dexamethasone in the rhomboid intercostal and subserratus plane block for thoracoscopic lobectomy analgesia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063391

Enrollment

Unknown

Registered

2022-09-05

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

R group:40 ml of ropivacaine 0.375%

RD group:40 ml of ropivacaine 0.375% + dexmedetomidine 1 µg /kg

RA group:40 ml of ropivacaine 0.375% + dexamethasone 8 mg

RDA group:40 ml of ropivacaine 0.375% + dexmedetomidine 1 µg /kg + dexamethasone 8 mg

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years 2. Body mass index was 15~30 kg/m2 3. The American Society of Anesthesiologists (ASA) classification is I ~ III level

Exclusion criteria

Exclusion criteria: 1. Severe heart and lung disease 2. Bradycardia 3. Cardiac conduction disease 4. Chronic pain treatment or chronic steroid therapy 5. Mental illness 6. Allergy to the study drugs

Design outcomes

Primary

Measure	Time frame
The duration of analgesia;	—

Secondary

Measure	Time frame
Oxycodone consumption during first 48 h postoperatively;NRS scores at different time after surgery;Postoperative adverse effects;	—

Countries

China

Contacts

Public ContactQingren Liu

Xishan People’s Hospital of Wuxi City

liuqr5250@163.com+86 13601510412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026